EGFR and neoplasm: The concurrent existence of PDL1 expression and high levels of CD8+ tumor infiltrating lymphocyte (TILs) were only present in a small group of EGFR mutant tumors, suggesting an underlying mechanism of anti-PD1/PDL1 resistance in patients with EGFR or ALK mutation (Gainor et al., 2016).